prikaz prve stranice dokumenta The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study
  Preuzmi
PDF 764.27 KB
Znanstveni rad - Prethodno/kratko priopćenje
The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study
Diabetology and Metabolic Syndrome, 10 (2018), 16; 1-5. https://doi.org/10.1186/s13098-018-0321-x
Božek, Tomislav; Bilić Ćurčić, Ines; Cigrovski Berković, Maja; Gradišer, Marina; Kurir Tićinović, Tina; Klobučar-Majanović, Sanja; Marušić, Srećko

Citirajte ovaj rad

Božek, T., Bilić Ćurčić, I., Cigrovski Berković, M., Gradišer, M., Kurir Tićinović, T., Klobučar Majanović, S. i Marušić, S. (2018). The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study. Diabetology and Metabolic Syndrome, 10. (16), 1-5. doi: 10.1186/s13098-018-0321-x

Božek, Tomislav, et al. "The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study." Diabetology and Metabolic Syndrome, vol. 10, br. 16, 2018, str. 1-5. https://doi.org/10.1186/s13098-018-0321-x

Božek, Tomislav, Ines Bilić Ćurčić, Maja Cigrovski Berković, Marina Gradišer, Tina Kurir Tićinović, Sanja Klobučar Majanović i Srećko Marušić. "The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study." Diabetology and Metabolic Syndrome 10, br. 16 (2018): 1-5. https://doi.org/10.1186/s13098-018-0321-x

Božek, T., et al. (2018) 'The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study', Diabetology and Metabolic Syndrome, 10(16), str. 1-5. doi: 10.1186/s13098-018-0321-x

Božek T, Bilić Ćurčić I, Cigrovski Berković M, Gradišer M, Kurir Tićinović T, Klobučar Majanović S, i sur.. The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study. Diabetology and Metabolic Syndrome [Internet]. 2018. [pristupljeno 02.12.2024.];10(16):1-5. doi: 10.1186/s13098-018-0321-x

T. Božek, et al., "The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study", Diabetology and Metabolic Syndrome, vol. 10, br. 16, str. 1-5, 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:945013. [Citirano: 02.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:945013
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study
AutorTomislav Božek
AutorInes Bilić Ćurčić
AutorMaja Cigrovski Berković
AutorMarina Gradišer
AutorTina Kurir Tićinović
AutorSanja Klobučar-Majanović
AutorSrećko Marušić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
INTRODUCTION: This observational study aimed to assess the effectiveness of lixisenatide as add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes. METHODS: Patients with diabetes type 2, prescribed with lixisenatide and basal insulin were divided in three groups (premixed insulin, basal bolus insulin and basal oral therapy (BOT). Difference in mean change in HbA1c, body mass index, total insulin doses, fasting blood glucose (FPG) and prandial blood glucose (PPG) were assessed after 3-6-months of follow-up. RESULTS: The primary outcomes were assessed in 111 patients. Lixisenatide added to basal insulin, reduced HbA1c and body weight significantly in all three groups of patients (p < 0.001 for all), with the most prominent reduction in the basal bolus group of patients which had the highest baseline HbA1c compared to premix and BOT treatment groups. Regarding a difference in total insulin dose the reduction was statistically significant in the basal bolus (p = 0.006) and premix group (p < 0.001). FPG and PPG were also significantly reduced over time in all three groups (p < 0.001 for all). A composite outcome (reduction of HbA1c below 7% (53 mmol/mol) with any weight loss) was achieved in 27% of total patients included in the study, reduction of HbA1c below 7% was observed in 30% of patients, while 90% of patients experienced weight reduction. CONCLUSION: These results indicate that lixisenatide add on basal insulin treatment (BIT) can improve glycemic control in a population with long- standing type 2 diabetes and previously uncontrolled on other insulin therapy.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prethodno/kratko priopćenje
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaDiabetology and Metabolic Syndrome
Brojčani podacivol. 10, br. 16, str. 1-5
p-ISSN1758-5996
DOIhttps://doi.org/10.1186/s13098-018-0321-x
URN:NBNurn:nbn:hr:184:945013
Datum objave publikacije2018
URL dokumentahttp://bib.irb.hr/932480
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-03-10 17:35:17